Nona Biosciences, Evive Biotech Partner on Antibody Discovery

Nona Biosciences, a company involved in antibody discovery and development solutions, and Evive Biotech, a global biopharmaceutical company developing a biologic therapies, entered into a collaboration agreement on antibody discovery using Nona Biosciences’ Harbour Mice antibody technology platform.

Harbour Mice is an antibody technology platform that utilizes the transgenic mouse to generate fully human monoclonal antibodies in both a traditional two heavy and two light chain (H2L2) format and a heavy chain only (HCAb) format. The platform has potential for the development of therapeutic antibodies and the acceleration of drug discovery and development.

“Nona Biosciences is committed to bringing antibody discovery and research solutions to our partners better and faster,” said Jingsong Wang, chairman of Nona Biosciences. “With the capabilities of Harbour Mice, we look forward to empowering our partners in antibody drug discovery and development, and helping more patients benefit from cutting-edge technologies and therapies.”

“There is tremendous potential in antibody-based therapy, and I am very excited about this collaboration,” said Simon Li, CEO & CMO of Evive Biotech. “Evive Biotech’s mission is to develop innovative biologic therapies for patients worldwide. We eagerly anticipate collaborating with Nona Biosciences to accelerate the discovery of innovative antibody therapies to benefit patients across the globe.”